Choate Investment Advisors Purchases 26,019 Shares of Abbott Laboratories $ABT

Posted by Francis Steltz on May 25th, 2026

Choate Investment Advisors lifted its position in Abbott Laboratories (NYSE:ABT – Free Report) by 9.3% during the 4th quarter, Holdings Channel reports. The firm owned 305,976 shares of the healthcare product maker’s stock after buying an additional 26,019 shares during the quarter. Abbott Laboratories makes up 0.8% of Choate Investment Advisors’ investment portfolio, making the stock its 23rd biggest holding. Choate Investment Advisors’ holdings in Abbott Laboratories were worth $38,336,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ABT. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth about $27,000. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth about $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth about $31,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth about $33,000. Finally, Leonteq Securities AG bought a new stake in shares of Abbott Laboratories in the 4th quarter worth about $35,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ABT shares. Evercore lowered their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. TD Cowen decreased their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company decreased their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $119.43.

Get Our Latest Stock Analysis on ABT

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure

Abbott Laboratories Stock Up 0.0%

Shares of NYSE ABT opened at $87.42 on Monday. The firm has a market capitalization of $152.27 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The firm’s 50-day moving average is $96.74 and its 200-day moving average is $111.97.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock worth $353,097 over the last ninety days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.